COMP <GO>
TWST vs EXEL // EV/EBITDA & P/E VALUATION
Twist Bioscience Corporation (NASDAQ) VS. Exelixis Inc. (NASDAQ) • 15-METRIC TALLY: TWST 3
— EXEL 9
■ METRIC PARITY
LAST: $152.78 (-11.92%) • MKT CAP: $11.50B
valuation
—
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
valuation
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TWST VS. EXEL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TWST | EXEL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 94.20% | 96.00% | -1.80 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.70% | 35.10% | -46.80 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 18.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -0.66% | 5.34% | -6.00 | EXEL | /fcf-yield <GO> |
| Operating Margin | -4.20% | 37.60% | -41.80 | EXEL | /operating-margins <GO> |
| Net Profit Margin | -2.40% | 33.70% | -36.10 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 16.50% | 7.00% | +9.50 | TWST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 16.64 | +9.36 | TWST | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.2 | 63.3 | -6.10 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.96 | +0.02 | TWST | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 19.5x | +1.50 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.50B | $16.40B | -$4.90B | EXEL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TWST REV | EXEL REV | TWST GROSS % | EXEL GROSS % | TWST FCF | EXEL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $2.32B | — | 96.4% | -$75.6M | $875.8M |
| FY 2024 | $0 | $2.17B | — | 96.5% | -$69.2M | $671.5M |
| FY 2023 | $0 | $1.83B | — | — | -$142.5M | $251.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TWST // BETA 0.98
EXEL // BETA 0.96